Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 2/20 | 0.55 |
| ▸ | ANPEP | P15144 | 1/20 | 0.55 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.55 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.55 |
| ▸ | MME | P08473 | 4/20 | 0.54 |
| ▸ | ACE | P12821 | 2/20 | 0.54 |
| ▸ | CPA1 | P15085 | 2/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.54 |
| ▸ | GNPAT | O15228 | 1/20 | 0.54 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.51 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5812528 | 1.00 | LAP3 (0.55) | LAP3ANPEPRNPEPDNPEPMME | |
| SCHEMBL21570275 | 1.00 | LAP3 (0.55) | LAP3ANPEPRNPEPDNPEPMME | |
| SCHEMBL5812534 | 1.00 | LAP3 (0.55) | LAP3ANPEPRNPEPDNPEPMME | |
| SCHEMBL11415082 | 0.92 | LAP3 (0.57) | LAP3ANPEPRNPEPDNPEPMME | |
| SCHEMBL5812584 | 0.92 | LAP3 (0.57) | LAP3ANPEPRNPEPDNPEPMME | |
| SCHEMBL5812579 | 0.92 | LAP3 (0.57) | LAP3ANPEPRNPEPDNPEPMME | |
| SCHEMBL19173100 | 0.86 | GNPAT (0.60) | MMEACECPA1ACE2GNPAT | |
| SCHEMBL12475970 | 0.86 | GNPAT (0.60) | MMEACECPA1ACE2GNPAT | |
| SCHEMBL12475967 | 0.86 | GNPAT (0.60) | MMEACECPA1ACE2GNPAT | |
| SCHEMBL11414321 | 0.85 | MME (0.61) | LAP3ANPEPRNPEPDNPEPMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11426399-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | ALKAHEST, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2022-07-21 | — | — | US | disclosed |
| US-11344542-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | ALKAHEST, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3793602-A1 | TREATMENT OF AGING-ASSOCIATED DISEASE WITH MODULATORS OF LEUKOTRIENE A4 HYDROLASE | Alkahest, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20200368220-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20190350917-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344542-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LAP3 440/4885ANPEP 872/4885RNPEP 384/4885 |
| US-20190350917-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | LAP3 440/4885ANPEP 872/4885RNPEP 384/4885 |
| US-11426399-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LAP3 440/4885ANPEP 872/4885RNPEP 384/4885 |
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | LAP3 440/4885ANPEP 872/4885RNPEP 384/4885 |
| US-20200368220-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | LAP3 440/4885ANPEP 872/4885RNPEP 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.